Sun Pharmaceutical Live Share Price Today, Share Analysis and Chart

Q2FY27- Investor Call Audio Recording

Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q2FY27 Performance and Outlook. Listen to the full earnings transcript.

Board Meeting Outcome - Conclusion

Pharmaceuticals company Sun Pharmaceutical Industries announced Q2FY27 results Standalone Financial Highlights Revenue from Operations: Recorded at Rs 61,419.2 million in Q2FY27, showing a QoQ growth of 6.98% from Rs 57,411.3 million in Q1FY27 and a YoY growth of 35.04% from Rs 45,481.1 million in Q2FY26. For H1FY27, it reached Rs 118,830.5 million, a YoY growth of 17.16% from Rs 101,429.9 million in H1FY26. Total Income: Reached Rs 62,229.3 million in Q2FY27, registering a QoQ expansion of 5.81% from Rs 58,813.0 million in Q1FY27 and a YoY increase of 34.67% from Rs 46,209.0 million in Q2FY26. For H1FY27, it amounted to Rs 121,042.3 million, up 17.29% YoY compared to Rs 103,194.9 million in H1FY26. Profit Before Tax (PBT): Totaled Rs 12,029.9 million in Q2FY27, marking a QoQ decline of 19.07% from Rs 14,864.5 million in Q1FY27 but climbing 79.08% YoY from Rs 6,717.5 million in Q2FY26. For H1FY27, standalone PBT stood at Rs 26,894.4 million, showcasing a YoY jump of 45.53% against Rs 18,480.1 million in H1FY26. Profit After Tax (PAT): Stood at Rs 8,712.9 million in Q2FY27, dropping 21.87% QoQ from Rs 11,151.4 million in Q1FY27 but expanding 54.42% YoY against Rs 5,642.2 million in Q2FY26. For H1FY27, standalone PAT reached Rs 19,864.3 million, climbing by 51.72% YoY from Rs 13,092.8 million in H1FY26. Earnings Per Share (EPS): Basic EPS was recorded at Rs 3.6 in Q2FY27, down 21.74% QoQ from Rs 4.6 in Q1FY27 but up 50.00% YoY from Rs 2.4 in Q2FY26. For H1FY27, basic EPS came in at Rs 8.3, gaining 50.91% YoY over Rs 5.5 in H1FY26. Consolidated Financial Highlights Revenue from Operations: Stood at Rs 161,987.1 million in Q2FY27, increasing 5.87% QoQ from Rs 152,998.8 million in Q1FY27 and 11.88% YoY from Rs 144,783.1 million in Q2FY26. For H1FY27, it arrived at Rs 314,985.9 million, growing 11.19% YoY from Rs 283,297.1 million in H1FY26. Total Income: Logged at Rs 167,160.3 million in Q2FY27, up 4.32% QoQ from Rs 160,235.0 million in Q1FY27 and up 11.83% YoY against Rs 149,482.3 million in Q2FY26. For H1FY27, it reached Rs 327,395.3 million, up 11.88% YoY from Rs 292,640.9 million in H1FY26. Profit Before Tax (PBT): Arrived at Rs 31,593.7 million in Q2FY27, showing a QoQ decline of 22.92% from Rs 40,988.1 million in Q1FY27 and a YoY drop of 24.19% from Rs 41,676.1 million in Q2FY26. For H1FY27, consolidated PBT touched Rs 72,581.8 million, falling 1.12% YoY from Rs 73,403.8 million in H1FY26. Profit After Tax (PAT): Reported at Rs 19,885.3 million in Q2FY27, shrinking 31.31% QoQ from Rs 28,947.9 million in Q1FY27 and dipping 36.22% YoY from Rs 31,179.5 million in Q2FY26. For H1FY27, consolidated PAT reached Rs 48,833.2 million, translating to a YoY contraction of 9.51% from Rs 53,966.8 million in H1FY26. Earnings Per Share (EPS): Basic EPS was reported at Rs 8.3 in Q2FY27, displaying a decrease of 31.40% QoQ from Rs 12.1 in Q1FY27 and a drop of 36.15% YoY from Rs 13.0 in Q2FY26. For H1FY27, basic EPS stood at Rs 20.4, displaying a 9.33% YoY decline from Rs 22.5 in H1FY26. Business Highlights & Segment Performance: India Formulations: Sales in India recorded Rs 55,522.8 million for Q2FY27, up by 17.3% YoY compared to Rs 47,347.9 million in Q2FY26. For H1FY27, India formulation sales reached Rs 110,271.7 million, posting a 16.6% growth over H1FY26. US Formulations: Formulation sales in the US market reached Rs 43,471.0 million (USD 455 million) during Q2FY27, registering a YoY decline of 8.2% from Rs 43,287.9 million (USD 496 million) in Q2FY26 due to Lenalidomide erosion impact. For H1FY27, US formulation sales stood at Rs 83,890.1 million (USD 882 million). Emerging Markets Formulations: Sales brought in Rs 33,402.5 million (USD 350 million) for Q2FY27, scaling up by 7.6% YoY from Rs 28,366.9 million (USD 325 million) in Q2FY26. For H1FY27, segment sales totaled Rs 62,858.8 million (USD 661 million). Rest of World (ROW) Formulations: Delivered sales of Rs 23,040.0 million (USD 241 million) during Q2FY27, growing by 3.1% YoY over Rs 20,414.9 million (USD 234 million) in Q2FY26. For H1FY27, sales stood at Rs 43,725.8 million (USD 460 million). Active Pharmaceutical Ingredients (API): External API sales recorded Rs 4,888.6 million in Q2FY27, moving up 13.7% YoY from Rs 4,298.7 million in Q2FY26. For H1FY27, external API sales reached Rs 10,860.9 million, posting a YoY increase of 11.9%. Acquisition Updates: During Q2FY27, the Group completed a 100% equity share purchase of Innovcare Lifesciences Private Limited for a total consideration of Rs 2,711.9 million. Regulatory filings for the acquisition of Organon & Co. have also been completed in a majority of target regions. Rick Ascroft, North America CEO, Sun Pharma, said: "FDA approval of ILUMYA for adults with active psoriatic arthritis represents another important innovative medicine milestone for Sun Pharma and builds on the established clinical experience of ILUMYA in plaque psoriasis.” "As an IL-23 inhibitor administered exclusively by a healthcare provider, ILUMYA is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care." Philip Mease, Director of Rheumatology Research at the Swedish Medical Center and Providence St Joseph Health & Clinical Professor at the University of Washington School of Medicine, Seattle, WA: "Psoriatic arthritis is a complex and chronic disease. As clinicians, we need a range of therapeutic options that allow us to individualize care based on each patient’s symptoms and treatment goals. Adding an IL-23 inhibitor option that is administered by a healthcare provider gives us a new way to offer appropriate patients additional support and engagement with their healthcare team.” Result PDF

Unaudited Financial Results for the quarter and half year ended 30 September 2026